

五鼎生技
APEXBIO
T a i w a n

2021 3Q

2021 Dec

APEXBIO

Company profile

Stock #	TSEC 1733
Industry	IVD Medical Device
Operation Locations	<p>Head quarter: No. 7, Li-Hsin 5th Rd., Hsinchu Science Park, Hsinchu, Taiwan</p> <p>Tao Yuan Factory: No. 180, Lane 70, Wuqing Rd., Dayuan Dist., Taoyuan City 337, Taiwan</p> <p>Suzhou Corp.: Room 106, No.2, Kecheng Road, SIP, Suzhou, China</p> <p>Omnis Health LLC : 1309 Elm Hill Pike, Nashville, TN 37210, USA</p>
Started	12/02/1997
IPO	06/13/2000(4101 OTC) 09/17/2001(1733 TSEC)
Capital	NTD 1 Billion
Chairman/CEO	Thomas Shen PhD
Employees	712 people (upto 9/30/2021)

Milestone

1997 ApexBio set-up
1998 BGM FDA 510K approval
1999 Uric Acid patent granted
2000 IPO listed to Taiwan OTC
2001 Transit IPO listed to TSEC

2007 Lactate launch
2008 Voice BGM launch
2009 Taoyuan factory set-up
2010 Tele-health tech build-up
2011 AEO certified by Customs Admin

2017 Acquired Omnis Health LLC
Brazil ANVISA notified
2018 ivCGM production set-up
Ket-1 FDA 510K approval
2019 ISO45001:2018 notified
2020 GCTU CE approval

1997-2001

2002-2005

2006-2011

2012-2015

2016-2020

2002 ISO 9001/13485 notified
2003 CE IVDD notified
2005 Pesticide residues check
product launch



2012 ApexBio Suzhou Corp set-up
2013 1st Taiwan MITTELSTAND Award
from MOEA
2015 HbA1C/MultiSure GK products launch
APEA Award Outstanding Category
ISO14001/OHSAS18001 notified

Quality system

Region	The Authority	Regulatory compliance
Taiwan	TFDA	GMP
EU	CE	ISO 13485:2016 CE mark number:CE0197 EN ISO 15197:2015
USA	FDA	510K's FDA on-site audit w/o 483 citations 2001/2006/2011/2016
China	CFDA	Medical Device Class II
Japan	PMDA	
Brazil	ANVISA	2017 passed on-site audit

ESH policy

In response to environmental protection and occupational safety and health policies, management procedures have been established year by year to consistently comply with the GRI guidelines in order to achieve the goal of sustainable of enterprises.



Product portfolio

Blood glucose monitoring systems



Professional Monitoring systems



- Uric Acid
- Hemoglobin
- Lactate
- Ketone
- HbA1C

Multi-functional systems



- Glucose + Uric Acid
- Glucose + Ketone
- Glucose + Cholesterol
- Glucose + Cholesterol + Triglycerides + Uric Acid



GLUCOSURE POC

Glucose/Ketone POC barcode scanner + wifi

KETOSURE™ POC

BLOOD KETONE MONITORING SYSTEM

Ketone POC barcode scanner + wifi



 Hospital use

APEXBIO

Eclipse PLUS

Eclipse
MULTI-PURPOSE ANALYZER **PLUS**

- Hemoglobin A1c
- Microalbumin
- Creatinine
- Albumin Creatinine Ratio (ACR)



Specifications


- Display: 5" Full Color LCD
- Display Unit:
 - HbA1c: %, mmol/mol, eAG
 - Microalbumin: mg/dL
 - Creatinine: mg/dL, mmol/L
 - ACR: mg/g, mg/mmol
- Operating/User Interface: Touch Panel Screen
- Data Port: Type-A USB
- Power Supply: 100-240V, 50/60Hz
- Dimension: 290L x 206W x 137H (mm)
- Weight: 1.6kg
- Operating Condition:
 - Temperature: 18-35°C/Humidity: <80%
- Analyzer Storage Condition:
 - Temperature: 4-50°C/Humidity: <80%
- Cartridge Storage Temperature:
 - HbA1c: 2-8°C
 - Microalbumin: 4-30°C
 - Creatinine: 4-30°C
 - ACR: 4-30°C
- Accessories: Optical Control Cartridge, Barcode Scanner, Printer, USB Cable, Power Adaptor



APEX BIOTECHNOLOGY CORP.,
No. 7, L-Hsin 5th Rd., Hsinchu Science Park,
Hsinchu, Taiwan
Tel: 886-3-6641852 / Fax: 886-3-6676302
E-mail: info@apexbio.com / Website: www.apexbio.com



Eclipse
MULTI-PURPOSE ANALYZER **PLUS**



APEXBIO


For Clinic and
Hospital use

Early diagnosis of
diabetic nephropathy
--Microalbumin
--Creatinine
--ACR

APEXBIO

Customized projects

- Product platform focus on electrochemistry/photometry/immunology
- To derive new parameter tests and optimize our core platform.
- Sharing our advantage of regulation/quality control/sales channels/clinical trails/manufacturing to alliance with partners and customers.
- Integrate to IOT with hospitals and healthcare service centers



Global sales distribution



Territory	2019	2020	2021/1-3Q
America	41%	42%	43%
EU	48%	46%	46.5%
Asia	10%	11%	10%
Africa	1%	1%	0.5%


Finance Performance

	2019	2020	2021/1-3Q
Revenue	2,198,862	2,005,337	1,570,342
Gross margin	590,577	452,224	425,998
Operation profit	203,276	103,328	156,725
Profit after tax	112,978	94,629	120,755
EPS	1.14	0.95	1.21
G/M ratio	27%	22%	27%
Shipped Meter Qty (kit)	1,800K	1,731K	1,178K
Shipped Strip Qty(pcs)	1,127M	1,061M	872M

Product ratio

2020

■ BGM & A1C ■ Electrode
■ Non-BGM ■ 其他(附件)




Non-BGM

Hemoglobin/Ketone/UricAcid/Lactate/Cholesterol/
Pesticide quick check etc

2021/ 1-3Q

■ BGM & A1C ■ Electrode
■ Non-BGM ■ Others



the 7th Corporate Governance Evaluation (2020)

Category	Total number of indicators		weighting		Points for satisfied indicators		Number of inapplicable indicators		Extra Credit Indicators:	
	2019	2020	2019	2020	2019	2020	2019	2020	2019	2020
Protecting Shareholder Rights and Interests and Treating Shareholders Equitably	17	16	0.2	0.19	13	14	0	0	1	0
Enhancing Board Composition and Operation	29	28	0.35	0.34	20	20	0	0	2	3
Increasing Information Transparency	21	21	0.24	0.26	12	12	0	0	0	0
Putting Corporate Social Responsibility into Practice	18	17	0.21	0.21	16	15	0	0	2	3
others	2	2	-	-	-	-	-	-	-	-

Total score : 80.3

Ranking (SEC): 21%~35%

Thank you